Bardak, Handan Isparta Özel Kariyer Göz Hastanesi, Turkey , Günay, Murat Zeynep Kamil Kadın ve Çocuk Hastalıkları Eğitim Araştırma Hastanesi - Göz Hastalıkları Kliniği, Turkey , Ekim, Mustafa Muhterem Isparta Özel Kariyer Göz Hastanesi, Turkey , Bardak, Yavuz Isparta Özel Kariyer Göz Hastanesi, Turkey , Bardak, Yavuz Süleyman Demirel Üniversitesi - Tıp Fakültesi - Göz Hastalıkları AD, Turkey

Shortto tpeircmal enfefepcat foenf acoc mtrbeiantemde inntt rianv rietrferaacl ttoriraym dciainboeltoicn em-abceuvlaacri zeudmemaba with

15672

Purpose: To investigate the short term effect of combined intravitreal triamcinolone acetonide (IVTA) and bevacizumab (IVB) injection with topical nepafenac in diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor. Material and Methods: 16 eyes of 16 patients with refractory DME were included the study. IVTA (2mg 0.05ml) and IVB (1.25mg 0.05ml) combined injection was performed and topical nepafenac was applied for three months. Ocular examination of patients was made, corrected visual acuity (CVA) and central macular thickness (CMT) repeated before the injection, 1 month and 3 months after the injection. Results: Nine (56 %) patients were women and 7 (44 %) patients were men and their mean age was 62,75±5,73 years. Before treatment CMT was 437.44±76.34 micron and 1 month after combined injection CMT was 366.56±61.15 micron and 3 months after CMT was 309.75±61.17 micron. There was significant reduction in CMT 1 month and 3 months after injection (p 0.05) with respect to CMT before treatment. Before treatment CVA was 1.29±0.84 Log Mar and 1 month after combined injection CVA was 0.93±0.74 Log Mar and 3 months after CVA was 0.89±0.72 Log Mar. There was significant change in CVA 1 month and 3 months after injection (p 0.05) with respect to CVA before treatment. Three months after combined injection 10 (62.5 %) patients needed intravitreal injection. Conclusion: Combined IVTAIVB injection together with topical nepafenac treatment is safe and effective procedure in DME refractory to anti-VEGF therapy.

10

Bevacizumab , diabetic macular edema , nepafenac , triamcinolone acetonide

Medical Journal Of Suleyman Demirel University

15